Clearmind signs non-binding LOI with Polyrizon for intranasal drug delivery
Clearmind Medicine (CMND) has signed a non-binding Letter of Intent with Polyrizon (PLRZ) to develop a novel intranasal formulation for its ...
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...
Nasdaq1d
Clearmind Medicine To Develop Novel Intranasal Formulation With Polyrizon
(RTTNews) - Clearmind Medicine Inc. (CMND), Wednesday announced that the company has signed a non-binding Letter of Intent with Polyrizon Ltd. (PLRZ), a development stage biotech company ...
Nasdaq6d
Polyrizon Signs Non-Binding LOI To Develop Intranasal Psychedelic-Based Treatments With Partner
(RTTNews) - Polyrizon Ltd. (PLRZ), a development-stage biotech company, Friday announced that it has signed a non-binding Letter of Intent Or LOI with a biotech company focused on psychedelic ...
TMCnet2d
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
The collaboration will explore the potential of Clearmind’s proprietary drug candidate, 5-Methoxy-2-aminoindane (MEAI), alone or in combination with Palmitoylethanolamide (PEA), through intranasal ...
Yahoo Finance8d
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Investing2d
Clearmind and Polyrizon partner on nasal drug delivery
Clearmind will fund the research and development process, while Polyrizon will apply its proprietary intranasal drug delivery platform to the project. InvestingPro analysis shows the company ...
Yahoo Finance7d
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of ...
Morningstar2d
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
Under the terms of the non-binding LOI, Clearmind and Polyrizon will conduct research and development efforts to achieve a proof of concept for an intranasal formulation of MEAI and MEAI-PEA ...